See other indications for REVLIMID:
This site is intended for US audiences only.
This site is intended for US audiences only.
REVLIMID is a prescription medicine used to treat adults with follicular lymphoma (FL) or marginal zone lymphoma (MZL) in combination with a rituximab product, and who have previously been treated for their FL or MZL. FL and MZL are types of cancer of white blood cells called B-cell lymphocytes that are found in the lymph nodes and spleen. REVLIMID should not be used to treat people who have chronic lymphocytic leukemia (CLL) unless they are participants in a controlled clinical trial. It is not known if REVLIMID is safe and effective in children.
R2 IS A CHEMOTHERAPY-FREE COMBINATION THAT WAS TESTED IN LABORATORY STUDIES
This combination of REVLIMID and rituximab was shown to work with certain cells used by the immune system to attack the lymphoma cells.
In laboratory studies, REVLIMID and rituximab have been shown to help: